


Global Healthcare Data

Population

- Aging population (65+) is expected to grow 2.9% annually from 2020 to 2040 worldwide.
- China will see the most rapidly growing aging population and declining number of young people due to the increasing longevity and dropping birthrate.
- Olympus continues providing diagnosis and treatment solutions to the growing aging population.




*1 EU5: UK, France, Italy, Germany, Spain

Source: United Nations, Department of Economic and Social Affairs, Population Division (2024). World Population Prospects 2024, Online Edition.

Health Expenditure

- World healthcare expenditure per capita is growing at the compound annual growth rate (CAGR) of 2.3% from 2012 to 2022. The United States spends the most in healthcare expenditure per capita, while China has the largest CAGR of 9%.
- Olympus is contributing to improve healthcare access globally through supporting healthcare professionals training, etc.




*2 CAGR: 2012–2022


Source: World Bank, World Health Organization Global Health Expenditure database <https://data.worldbank.org/indicator/SH.XPD.CHEX.PC.CD?end=2022&start=2012&type=points&view=chart>

Cancer

- Lung, colorectal, prostate, stomach, and liver cancers will remain the top five by volume addressable cancers over the long term with significant growth in absolute incidence. Stomach cancer is projected to be the fastest growing and followed by cancers of the esophagus, pancreas and liver.
- The overall opportunity to improve the standard of care and patient outcomes will continue to grow significantly across Olympus-addressable cancers.



- Lung, colorectal, liver, stomach, and prostate cancers will remain the top five by volume of addressable cancer deaths over the long term. Deaths from prostate and bladder cancers are projected to be the fastest growing at a 130% and 114% increase, respectively, from 2022 to 2050.



* Selected cancers that Olympus is currently offering products and services for

Source: Ferlay J, Laversanne M, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Tomorrow (version 1.1). Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/tomorrow>, accessed July 31, 2024.


Disease Data

■ U.S. ■ EU5*1 ■ Japan ■ China

GI


Colorectal Cancer Patients

—Incidence by Selected Countries*2



Gastric Cancer Patients


—Incidence by Selected Countries*2



Respiratory

Non-small Cell Lung Cancer (NSCLC) Patients


—Incidence by Selected Countries*2



Urology


Bladder Cancer Patients

—Incidence by Selected Countries*2




BPH Patients

—Total Prevalence by Selected Countries*2



Kidney Stone Patients

—Total Prevalence by Selected Countries*2




Procedure Volume Data

GI*3

Colonoscopy

—Procedure Trend (U.S.)




Procedure Volume

17–20 M
(2023)

Gastroscopy

—Procedure Trend (U.S.)




Procedure Volume

8–12 M
(2023)

Endoscopic Retrograde Cholangio
Pancreatography (ERCP)

—Procedure Trend (U.S.)




Procedure Volume

500–
700 K
(2023)

Respiratory*4

Bronchoscopy

—Procedure Trend (U.S.)




Procedure Volume

1.3–1.7 M
(2023)

Urology*3

Cystoscopy

—Procedure Trend (U.S.)




Procedure Volume

3–5 M
(2023)

Ureteroscopy

—Procedure Trend (U.S.)




Procedure Volume

0.8–1.2 M
(2023)

Trans Urethral Resection of the Prostate (TURP)

—Procedure Trend (U.S.)



Procedure Volume

160–
230 K
(2023)

*1 EU5: UK, France, Italy, Germany, Spain

*2 Source: Epi Database, Cerner Enviza, as accessed July 2025

*3 Source: AcuityMD, Olympus estimation

*4 Olympus estimation